Related Experiment Video
Updated: Jan 19, 2026
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
Elimination of SOX2/OCT4-Associated Prostate Cancer Stem Cells Blocks Tumor Development and Enhances Therapeutic
Prasanna Kumar Vaddi1, Mark A Stamnes2, Huojun Cao3
1The Department of Pharmacology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA. Prasanna.vaddi@ucdenver.edu.
Abstract:
SOX2 and OCT4 are key regulators of embryonic stem cell pluripotency. They are overexpressed in prostate cancers and have been associated with cancer stem cell (CSC) properties. However, reliable tools for detecting and targeting SOX2/OCT4-overexpressing cells are lacking, limiting our understanding of their roles in prostate cancer initiation, progression, and therapeutic resistance. Here, we show that a fluorescent reporter called SORE6 can identify SOX2/OCT4-overexpressing prostate cancer cells. Among tumor cells, the SORE6 reporter identified a small fraction with CSC hallmarks: rapid self-renewal, the capability to form tumors and metastasize, and resistance to chemotherapies. Transcriptome and biochemical analyses identified PI3K/AKT signaling as critical for maintaining the SORE6+ population. Moreover, a SORE6-driven herpes simplex virus thymidine kinase (TK) expression construct could selectively ablate SORE6+ cells in tumors, blocking tumor initiation and progression, and sensitizing tumors to chemotherapy. This study demonstrates a key role of SOX2/OCT4-associated prostate cancer stem cells in tumor development and therapeutic resistance, and identifies the SORE6 reporter system as a useful tool for characterizing CSCs functions in a native tumor microenvironment.
Insights
A new SORE6 reporter identifies prostate cancer stem cells (CSCs) overexpressing SOX2 and OCT4. Targeting these cells with a SORE6-driven system blocks tumor growth and improves chemotherapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Stem Cell Research
Background:
- SOX2 and OCT4 are crucial for embryonic stem cell pluripotency.
- These factors are overexpressed in prostate cancer, correlating with cancer stem cell (CSC) properties.
- Lack of tools to detect and target SOX2/OCT4-overexpressing cells hinders research into their role in prostate cancer.
Purpose of the Study:
- To develop a tool for identifying and targeting SOX2/OCT4-overexpressing prostate cancer cells.
- To investigate the role of these cells in prostate cancer initiation, progression, and therapeutic resistance.
Main Methods:
- Development and application of a fluorescent reporter system (SORE6).
- Characterization of SORE6-positive cells for CSC hallmarks (self-renewal, tumor formation, metastasis, chemoresistance).
- Transcriptome and biochemical analyses to identify signaling pathways.
- Utilizing a SORE6-driven herpes simplex virus thymidine kinase (TK) construct for selective cell ablation.
Main Results:
- The SORE6 reporter successfully identified a subset of prostate cancer cells with CSC properties.
- PI3K/AKT signaling was found to be critical for maintaining the SORE6-positive CSC population.
- Selective ablation of SORE6-positive cells using the TK system inhibited tumor initiation and progression.
- Targeting SORE6-positive cells sensitized tumors to chemotherapy.
Conclusions:
- SOX2/OCT4-associated prostate cancer stem cells play a significant role in tumor development and therapeutic resistance.
- The SORE6 reporter system is a valuable tool for studying CSC functions in vivo.
- Targeting CSCs identified by SORE6 offers a potential therapeutic strategy for prostate cancer.
More Related Videos
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
08:03Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
Published on: October 20, 2015
Related Concept Videos
07:16Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:03Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
08:54Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer
07:29Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:34Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization